stockrowTwist Bioscience Corporation
TWST Healthcare Biotechnology
Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.
- Revenue
- +23.2%
- EPS
- −264.7%
- Free cash flow
- −7.23%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
Follow TWST
Alert me
Twist Bioscience Corporation (TWST) Total debt
Twist Bioscience Corporation's total debt at the end of fiscal 2025 was $15.0M, down 81.1% from $79.2M in fiscal 2023. At the end of the quarter to 30 June 2026 it was $15.0M. Over the past ten years it has ranged from $4.7M (fiscal 2020) to $81.3M (fiscal 2022); the current reading is higher than 67% of that period. Twist Bioscience Corporation ranks 215th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $15.0M | (81.05%) |
| FY2023 | $79.2M | (2.58%) |
| FY2022 | $81.3M | 48.55% |
| FY2021 | $54.7M | 1,055.15% |
| FY2020 | $4.7M | (38.76%) |
| FY2019 | $7.7M | (20.43%) |
| FY2018 | $9.7M | 6.16% |
| FY2017 | $9.2M | (18.13%) |
| FY2016 | $11.2M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $15.0M | 0.00% |
| Mar 2026 | $15.0M | 0.00% |
| Dec 2025 | $15.0M | 0.00% |
| Sep 2025 | $15.0M | 0.00% |
| 25 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| IBRX ImmunityBio, Inc. compare | $774.4M |
| TGTX TG Therapeutics, Inc. compare | $745.4M |
| CAI Caris Life Sciences,�Inc. compare | $393.3M |
| SYRE Spyre Therapeutics, Inc. compare | $387.1M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $341.3M |
| CYTK Cytokinetics, Incorporated compare | $174.4M |
| TWST Twist Bioscience Corporation | $15.0M |
| KRYS Krystal Biotech, Inc. compare | $8.3M |
| PTGX Protagonist Therapeutics, Inc. compare | $1.8M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on TWST
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement